| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
4
| Lindborg Stacy (Co-CEO) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 08/04/2023 |
4
| Lebovits Chaim (President & CEO) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 31,185 shares
@ $0 |
|
| 07/19/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
4
| Taylor Kirk (Chief Medical Officer) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 35,000 shares
@ $0
Granted 80,000 options to buy
@ $2.99, valued at
$239.2k
|
|
| 05/01/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/05/2023 |
SC 13G/A
| Ness Kevin Dean reports a 10% stake in Brainstorm Cell Therapeutics Inc. |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 01/04/2023 |
4
| Lindborg Stacy (Co-CEO) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 01/04/2023 |
4
| Lebovits Chaim (CEO) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 31,185 shares
@ $0 |
|
| 12/13/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/16/2022 |
8-K
| Quarterly results |
| 04/08/2022 |
4
| FRENKEL JACOB A (Director) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 50,000 options to buy
@ $0.75, valued at
$37.5k
|
|
| 03/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/28/2022 |
8-K
| Quarterly results |
| 03/14/2022 |
4
| Kern Ralph Dr. (COO and Chief Medical Officer) has filed a Form 4 on BRAINSTORM CELL THERAPEUTICS INC.|
Txns:
| Granted 35,885 shares
@ $0 |
|
| 02/14/2022 |
SC 13G
| Abbhi Investments, LLC reports a 6.7% stake in Brainstorm Cell Therapeutics Inc. |
|